Medicine and Dentistry
Neuroendocrine Tumor
100%
Stomach Adenocarcinoma
85%
Cancer
65%
Neoplasm
56%
Adenocarcinoma
55%
Malignant Neoplasm
43%
Nivolumab
40%
Gamma Urogastrone
40%
Epidermal Growth Factor Receptor 2
40%
Abdominal Cancer
40%
Immunotherapy
37%
Overall Survival
34%
Surgery
33%
Targeted Therapy
32%
Biological Marker
30%
Esophageal Squamous Cell Carcinoma
30%
Metastatic Carcinoma
28%
Treatment Response
25%
Gastroesophageal Junction
25%
Combination Therapy
23%
Diseases
21%
Acinic Cell Carcinoma
20%
Gastrointestinal Tract
20%
Dedifferentiated Liposarcoma
20%
Fusobacterium nucleatum
20%
Uterine Cancer
20%
Cancer of Unknown Primary Origin
20%
Abdominal Wall
20%
Clear Cell Renal Cell Carcinoma
20%
Arm
20%
Atezolizumab
20%
Capillary Hemangioma
20%
Programmed Death 1 Ligand 1
20%
Genitourinary System
20%
Well Differentiated Liposarcoma
20%
Pyogenic Granuloma
20%
Granuloma
20%
Diagnosis
20%
Standardized Uptake Value
20%
Esophageal Cancer
20%
Ferroptosis
20%
Disease Exacerbation
20%
Neuroendocrine Carcinoma
15%
Urinary System
13%
Immune Checkpoint Inhibitor
13%
Xenograft
12%
Tumor Progression
12%
Recurrent Disease
12%
Cancer Cell
11%
Immunity
10%
Keyphrases
Neuroendocrine Neoplasms
90%
Gastric Adenocarcinoma
85%
Tumor
50%
Adenocarcinoma of the Esophagogastric Junction
46%
Human Epidermal Growth Factor Receptor 2 (HER2)
40%
Gastroesophageal Adenocarcinoma
40%
Nivolumab
40%
Neuroendocrine Tumor
40%
Gastroesophageal Cancer
40%
Chemotherapy
31%
Overall Survival
28%
Targeted Therapy
27%
Esophageal Squamous Cell Carcinoma
26%
Advanced or Metastatic
26%
Small Intestine
25%
Programmed Death-ligand 1 (PD-L1)
24%
Esophageal Cancer
22%
Pathological Complete Response
22%
MD Anderson Cancer Center
21%
Emerging Therapeutics
21%
Genomic Profiling
20%
Post-resection
20%
Claudin-18
20%
Without Chemotherapy
20%
Slow-growing
20%
Therapy Response
20%
SMARCA4 Gene
20%
Urinary System
20%
Diffuse-type Gastric Adenocarcinoma
20%
Combination Therapy
20%
Diagnostic Approach
20%
Appendiceal Neuroendocrine Neoplasms
20%
Gastrointestinal Tract
20%
Risk Stratification
20%
Atypical Lipomatous Tumor
20%
Appendiceal
20%
Microsatellite Status
20%
FIGO Staging System
20%
CLDN18.2
20%
Center Experience
20%
Integrated Genomics
20%
Energy Sources
20%
Endometrial Cancer
20%
Advanced Esophageal Squamous Cell Carcinoma
20%
Gynecologic Tract
20%
Pancreatic Acinar Cell Carcinoma
20%
Clinicopathological Analysis
20%
Genomic Modeling
20%
Pyogenic Granuloma
20%
Esophagogastric Adenocarcinoma
20%
